EyeGate Pharmaceuticals Inc (EYEG.OQ)
0.49USD
8:11pm BST
$0.00 (+0.00%)
$0.49
$0.48
$0.49
$0.46
139,155
156,030
$2.42
$0.29
About
Overall
| Beta: | -- |
| Market Cap(Mil.): | $20.99 |
| Shares Outstanding(Mil.): | 17.20 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| EYEG.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 30.95 | 32.74 |
| EPS (TTM): | -1.30 | -- | -- |
| ROI: | -193.34 | 14.84 | 14.38 |
| ROE: | -241.44 | 16.34 | 16.07 |
BRIEF-Eyegate Announces $11.25 Million Public Offering
* PRICING OF PUBLIC OFFERING OF 35.2 MILLION SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 35.2 MILLION SHARES OF COMMON STOCK
BRIEF-EyeGate Issued New Patent For Iontophoretic Contact Lens Technology
* EYEGATE ISSUED NEW PATENT FOR IONTOPHORETIC CONTACT LENS TECHNOLOGY Source text for Eikon: Further company coverage:
BRIEF-Eyegate Receives FDA Feedback On Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel
* EYEGATE RECEIVES FDA FEEDBACK ON INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL
BRIEF-EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation Treatment
* EYEGATE COMPLETES ENROLLMENT AND RECEIVES MILESTONE PAYMENT FOR CONFIRMATORY PHASE 3 CLINICAL STUDY OF EGP-437 IN ANTERIOR UVEITIS Source text for Eikon: Further company coverage:
BRIEF-Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 Mln
* EYEGATE PHARMACEUTICALS FILES FOR POTENTIAL MIXED SHELF OF UP TO $20 MILLION - SEC FILING Source text: (https://bit.ly/2ugghJy) Further company coverage:
BRIEF-Eyegate Pharma Submits Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel
* EYEGATE PHARMA SUBMITS INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL
BRIEF-Eyegate Announces Top-Line Results For Phase 2B Trial Of EGP-437 In Cataract Surgery
* EYEGATE ANNOUNCES TOP-LINE RESULTS FOR PHASE 2B TRIAL OF EGP-437 IN CATARACT SURGERY
BRIEF-Eyegate Promotes Sarah Romano To CFO
* EYEGATE PHARMACEUTICALS-ANNOUNCED PROMOTION OF SARAH ROMANO FROM INTERIM CFO TO CFO, EFFECTIVE JANUARY 1, 2018 Source text for Eikon: Further company coverage:
BRIEF-EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone Payment
* EYEGATE ACHIEVES 75% ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL TRIAL FOR ANTERIOR UVEITIS TRIGGERING MILESTONE PAYMENT
BRIEF-Eyegate Pharmaceuticals posts Q3 net loss $4.1 mln vs $3.4 mln a year ago
* Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update
Estimates